SCHEMBL11286320

SCHEMBL11286320

CC(=O)OCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.65
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.36
MAP2K1 Q02750 5/20 0.36
ALDH1A1 P00352 2/20 0.35
EGFR P00533 1/20 0.35
SRC P12931 1/20 0.35
MAP2K2 P36507 1/20 0.33
PRKCZ Q05513 1/20 0.33
IARS2 Q9NSE4 1/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9389982 0.96 LMNA (0.61) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL9316969 0.95 LMNA (0.60) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL8906487 0.95 LMNA (0.60) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL9451103 0.94 LMNA (0.59) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL9352729 0.94 LMNA (0.59) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL22662268 0.93 LMNA (0.57) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL10044836 0.92 LMNA (0.57) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL10044854 0.91 LMNA (0.56) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL12885813 0.89 LMNA (0.80) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1
SCHEMBL13246459 0.89 LMNA (0.69) LMNACYP2C19HIF1ASMN1; SMN2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023117667-A1 PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOISOPHTHALIC BISAMIDES BRACCO IMAGING SPA (IT) 2023-06-29 WO disclosed
US-20210284597-A1 Process for the Monotopic Preparation of Intermediate Organo-Iodinated Compounds for the Synthesis of Ioversol GUERBET (FR) 2021-09-16 US disclosed
US-4352788-A ARTERIES BRACCO INDUSTRIA CHIMICA S.P.A. (IT) 1982-10-05 US disclosed
US-4348377-A RADIOPACITY BRACCO INDUSTRIA CHIMICA S.P.A. (IT) 1982-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284597-A1 Process for the Monotopic Preparation of Intermediate Organo-Iodinated Compounds for the Synthesis of Ioversol PPIP5K2, TPO, TALDO1 LMNA 2390/4885CYP2C19 382/4885HIF1A 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.